Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Leighl, N. B., Redman, M. W., Rizvi, N., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Wade, J. L., Irvin, W. J., Reddy, S. C., Crawford, J., Bradley, J. D., Stinchcombe, T. E., Ramalingam, S. S., Miao, J., Minichiello, K., Herbst, R. S., Papadimitrakopoulou, V. A., Kelly, K., & Gandara, D. R. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer, 9(8), e002973. https://doi.org/10.1136/jitc-2021-002973
Authors:
Natasha B Leighl
Mary W Redman
Naiyer Rizvi
Fred R Hirsch
Philip C Mack
Lawrence H Schwartz
James L Wade
William J Irvin
Sreekanth C Reddy
Jeffrey Crawford
Jeffrey D Bradley
Thomas E Stinchcombe
Suresh S Ramalingam
Jieling Miao
Katherine Minichiello
Roy S Herbst
Vassiliki A Papadimitrakopoulou
Karen Kelly
David R Gandara
Affiliated Authors:
Naiyer Rizvi
Lawrence H Schwartz
Columbia Affiliation:
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Advancements in Lung Cancer Research (OpenAlex Topic)
Diagnosis and Treatment of Lung Cancer (OpenAlex Topic)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Carcinoma, Squamous Cell (MeSH)
Immunotherapy (MeSH)
Lung Neoplasms (MeSH)
Author Keywords:
combination
ctla-4 antigen
drug therapy
immunotherapy
lung neoplasms
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2021-002973
PMID:
34429332
DOI:
10.1136/jitc-2021-002973
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record

Record Created: